Xov xwm

NEW DELHI, Lub Rau Hli 22 (Xinhua) — Covaxin uas yog lub tuam txhab tsim tshuaj tiv thaiv kab mob hauv Is Nrias teb, Bharat Biotech, tau qhia tias muaj txiaj ntsig zoo txog 77.8 feem pua ​​hauv kev sim theem III, ntau lub xov xwm hauv zos tau tshaj tawm rau hnub Tuesday.

"Bharat Biotech's Covaxin muaj txiaj ntsig zoo 77.8 feem pua ​​​​​​hauv kev tiv thaiv COVID-19, raws li cov ntaub ntawv los ntawm theem III kev sim ua rau 25,800 tus neeg koom nrog thoob plaws Is Nrias teb," daim ntawv tshaj tawm hais.

Tus nqi ntawm kev ua tau zoo tau tshaj tawm rau hnub Tuesday tom qab Pawg Neeg Saib Xyuas Tshuaj Yeeb (Drugs Controller General of India) (DCGI) pawg kws tshaj lij (SEC) tau ntsib thiab tham txog cov txiaj ntsig.

Lub tuam txhab tshuaj tau xa cov ntaub ntawv sim theem III rau cov tshuaj tiv thaiv rau DCGI thaum kawg lub lim tiam.

Cov ntawv ceeb toom tau hais tias lub tuam txhab yuav tsum tuav lub rooj sib tham "ua ntej xa" nrog cov tub ceev xwm ntawm Lub Koom Haum Kev Noj Qab Haus Huv Ntiaj Teb rau hnub Wednesday, los tham txog cov lus qhia rau kev xa cov ntaub ntawv thiab cov ntaub ntawv xav tau zaum kawg.

Is Nrias teb tau pib txhaj tshuaj tiv thaiv COVID-19 rau lub Ib Hlis 16 los ntawm kev muab ob hom tshuaj tiv thaiv kab mob uas ua hauv Is Nrias teb, hu ua Covishield thiab Covaxin.

Lub koom haum Serum Institute of India (SII) yog tus tsim cov tshuaj AstraZeneca-Oxford University's Covishield, thaum Bharat Biotech tau koom tes nrog Indian Council of Medical Research (ICMR) hauv kev tsim cov tshuaj Covaxin.

Cov tshuaj tiv thaiv Sputnik V uas ua los ntawm Lavxias kuj tau muab tso tawm hauv lub tebchaws.